Shots: The biosimilar launch in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]readmore
Tags : Zirabev
Biosimilars
Regulatory
Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for
Shots: The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin, in patients with advanced non-sq NSCLC The study resulted in biosimilarity data, showing clinical […]readmore